Survival in patients with limited-stage peripheral T-cell lymphomas

Robert Briski, Andrew L Feldman, Nathaniel G. Bailey, Megan S. Lim, Kay Ristow, Thomas Matthew Habermann, William R. Macon, David J. Inwards, Joseph P. Colgan, Grzegorz S Nowakowski, Mark S. Kaminski, Thomas Elmer Witzig, Stephen Maxted Ansell, Ryan A. Wilcox

Research output: Contribution to journalArticle

10 Citations (Scopus)

Abstract

The natural history of limited-stage peripheral T-cell lymphoma (PTCL) remains poorly defined. Therefore, we examined outcomes in patients with the most common PTCL subtypes (PTCL, not otherwise specified [PTCL, NOS], angioimmunoblastic T-cell lymphoma [AITL], anaplastic large cell lymphoma [ALCL]) and limited-stage disease. In this retrospective, multicenter study, 75 patients with limited-stage disease were identified. The median event-free survival (EFS) and overall survival (OS) observed were 2.1 and 6.5 years, respectively. In a landmark analysis excluding patients with primary refractory disease, no significant benefit was observed for patients undergoing consolidative radiation therapy. With the exception of patients undergoing salvage hematopoietic stem cell transplant, survival following disease relapse or progression was poor, thus highlighting the need for improved therapeutic strategies.

Original languageEnglish (US)
Pages (from-to)1665-1670
Number of pages6
JournalLeukemia and Lymphoma
Volume56
Issue number6
DOIs
StatePublished - Jun 1 2015

Fingerprint

Peripheral T-Cell Lymphoma
Survival
Anaplastic Large-Cell Lymphoma
T-Cell Lymphoma
Hematopoietic Stem Cells
Natural History
Multicenter Studies
Disease-Free Survival
Cell Survival
Radiotherapy
Retrospective Studies
Transplants
Recurrence

Keywords

  • Peripheral T-cell lymphoma
  • Prognosis
  • Radiation

ASJC Scopus subject areas

  • Hematology
  • Oncology
  • Cancer Research

Cite this

Survival in patients with limited-stage peripheral T-cell lymphomas. / Briski, Robert; Feldman, Andrew L; Bailey, Nathaniel G.; Lim, Megan S.; Ristow, Kay; Habermann, Thomas Matthew; Macon, William R.; Inwards, David J.; Colgan, Joseph P.; Nowakowski, Grzegorz S; Kaminski, Mark S.; Witzig, Thomas Elmer; Ansell, Stephen Maxted; Wilcox, Ryan A.

In: Leukemia and Lymphoma, Vol. 56, No. 6, 01.06.2015, p. 1665-1670.

Research output: Contribution to journalArticle

Briski, R, Feldman, AL, Bailey, NG, Lim, MS, Ristow, K, Habermann, TM, Macon, WR, Inwards, DJ, Colgan, JP, Nowakowski, GS, Kaminski, MS, Witzig, TE, Ansell, SM & Wilcox, RA 2015, 'Survival in patients with limited-stage peripheral T-cell lymphomas', Leukemia and Lymphoma, vol. 56, no. 6, pp. 1665-1670. https://doi.org/10.3109/10428194.2014.963078
Briski, Robert ; Feldman, Andrew L ; Bailey, Nathaniel G. ; Lim, Megan S. ; Ristow, Kay ; Habermann, Thomas Matthew ; Macon, William R. ; Inwards, David J. ; Colgan, Joseph P. ; Nowakowski, Grzegorz S ; Kaminski, Mark S. ; Witzig, Thomas Elmer ; Ansell, Stephen Maxted ; Wilcox, Ryan A. / Survival in patients with limited-stage peripheral T-cell lymphomas. In: Leukemia and Lymphoma. 2015 ; Vol. 56, No. 6. pp. 1665-1670.
@article{b4b95ae3ec9b48ca862d3e7cb512e959,
title = "Survival in patients with limited-stage peripheral T-cell lymphomas",
abstract = "The natural history of limited-stage peripheral T-cell lymphoma (PTCL) remains poorly defined. Therefore, we examined outcomes in patients with the most common PTCL subtypes (PTCL, not otherwise specified [PTCL, NOS], angioimmunoblastic T-cell lymphoma [AITL], anaplastic large cell lymphoma [ALCL]) and limited-stage disease. In this retrospective, multicenter study, 75 patients with limited-stage disease were identified. The median event-free survival (EFS) and overall survival (OS) observed were 2.1 and 6.5 years, respectively. In a landmark analysis excluding patients with primary refractory disease, no significant benefit was observed for patients undergoing consolidative radiation therapy. With the exception of patients undergoing salvage hematopoietic stem cell transplant, survival following disease relapse or progression was poor, thus highlighting the need for improved therapeutic strategies.",
keywords = "Peripheral T-cell lymphoma, Prognosis, Radiation",
author = "Robert Briski and Feldman, {Andrew L} and Bailey, {Nathaniel G.} and Lim, {Megan S.} and Kay Ristow and Habermann, {Thomas Matthew} and Macon, {William R.} and Inwards, {David J.} and Colgan, {Joseph P.} and Nowakowski, {Grzegorz S} and Kaminski, {Mark S.} and Witzig, {Thomas Elmer} and Ansell, {Stephen Maxted} and Wilcox, {Ryan A.}",
year = "2015",
month = "6",
day = "1",
doi = "10.3109/10428194.2014.963078",
language = "English (US)",
volume = "56",
pages = "1665--1670",
journal = "Leukemia and Lymphoma",
issn = "1042-8194",
publisher = "Informa Healthcare",
number = "6",

}

TY - JOUR

T1 - Survival in patients with limited-stage peripheral T-cell lymphomas

AU - Briski, Robert

AU - Feldman, Andrew L

AU - Bailey, Nathaniel G.

AU - Lim, Megan S.

AU - Ristow, Kay

AU - Habermann, Thomas Matthew

AU - Macon, William R.

AU - Inwards, David J.

AU - Colgan, Joseph P.

AU - Nowakowski, Grzegorz S

AU - Kaminski, Mark S.

AU - Witzig, Thomas Elmer

AU - Ansell, Stephen Maxted

AU - Wilcox, Ryan A.

PY - 2015/6/1

Y1 - 2015/6/1

N2 - The natural history of limited-stage peripheral T-cell lymphoma (PTCL) remains poorly defined. Therefore, we examined outcomes in patients with the most common PTCL subtypes (PTCL, not otherwise specified [PTCL, NOS], angioimmunoblastic T-cell lymphoma [AITL], anaplastic large cell lymphoma [ALCL]) and limited-stage disease. In this retrospective, multicenter study, 75 patients with limited-stage disease were identified. The median event-free survival (EFS) and overall survival (OS) observed were 2.1 and 6.5 years, respectively. In a landmark analysis excluding patients with primary refractory disease, no significant benefit was observed for patients undergoing consolidative radiation therapy. With the exception of patients undergoing salvage hematopoietic stem cell transplant, survival following disease relapse or progression was poor, thus highlighting the need for improved therapeutic strategies.

AB - The natural history of limited-stage peripheral T-cell lymphoma (PTCL) remains poorly defined. Therefore, we examined outcomes in patients with the most common PTCL subtypes (PTCL, not otherwise specified [PTCL, NOS], angioimmunoblastic T-cell lymphoma [AITL], anaplastic large cell lymphoma [ALCL]) and limited-stage disease. In this retrospective, multicenter study, 75 patients with limited-stage disease were identified. The median event-free survival (EFS) and overall survival (OS) observed were 2.1 and 6.5 years, respectively. In a landmark analysis excluding patients with primary refractory disease, no significant benefit was observed for patients undergoing consolidative radiation therapy. With the exception of patients undergoing salvage hematopoietic stem cell transplant, survival following disease relapse or progression was poor, thus highlighting the need for improved therapeutic strategies.

KW - Peripheral T-cell lymphoma

KW - Prognosis

KW - Radiation

UR - http://www.scopus.com/inward/record.url?scp=84932168026&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84932168026&partnerID=8YFLogxK

U2 - 10.3109/10428194.2014.963078

DO - 10.3109/10428194.2014.963078

M3 - Article

C2 - 25248884

AN - SCOPUS:84932168026

VL - 56

SP - 1665

EP - 1670

JO - Leukemia and Lymphoma

JF - Leukemia and Lymphoma

SN - 1042-8194

IS - 6

ER -